The United States FDA has approved this drug following the biologics license application submission for zolbetuximab as a first-line treatment for locally advanced unresectable or metastatic HER2-negative G/GEJ adenocarcinoma with Claudin 18.2 positive tumours. Here, ERBB2 is linked to adenocarcinoma.